Depletion of CIP2A via siRNA in hepatocellular carcinoma, breast cancer and esophageal cancer not only decreased cancer cell proliferation but also sensitized cancer cells to chemotherapeutical agents like bortezomib and tumor necrosis factor. This evidence concerns the gene CIP2A and hepatocellular carcinoma.